CVM - CEL-SCI Corp Stock Price, Fair Value and News

1.42USD-0.03 (-2.07%)Market Closed

Market Summary

USD1.42-0.03

Market Closed

-2.07%

CVM Stock Price

View Fullscreen

CVM RSI Chart

CVM Valuation

Market Cap

71.1M

Price/Earnings (Trailing)

-2.29

Price/Sales (Trailing)

253.36

EV/EBITDA

-3.77

Price/Free Cashflow

-3.04

CVM Price/Sales (Trailing)

CVM Profitability

EBT Margin

-7536.20%

Return on Equity

-245.45%

Return on Assets

-108.15%

Free Cashflow Yield

-32.93%

CVM Fundamentals

CVM Revenue

Revenue (TTM)

462.8K

CVM Earnings

Earnings (TTM)

-31.1M

Earnings Growth (Yr)

14.57%

Earnings Growth (Qtr)

12.07%

Breaking Down CVM Revenue

Last 7 days

-9.0%

Last 30 days

-24.9%

Last 90 days

-50.7%

Trailing 12 Months

-33.3%

How does CVM drawdown profile look like?

CVM Financial Health

Current Ratio

1.26

CVM Investor Care

Shares Dilution (1Y)

14.55%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2019	469.7K	466.2K	462.8K	0
2018	0	0	476.6K	473.1K
2017	207.5K	342.0K	0	0
2016	98.0K	85.5K	73.0K	0
2015	116.9K	112.5K	110.5K	0
2014	120.0K	121.4K	122.9K	120.2K
2013	116.6K	116.8K	117.1K	118.5K
2012	536.1K	326.1K	116.1K	116.3K
2011	554.7K	755.4K	956.2K	746.1K
2010	0	116.7K	153.3K	354.0K
2009	0	0	80.1K	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of CEL-SCI Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 29, 2024	talor eyal	acquired	2,398	1.91	1,256	chief scientific officer
Mar 29, 2024	kersten geert r	acquired	5,174	1.91	2,709	chief executive officer
Mar 29, 2024	prichep patricia b	acquired	4,289	1.91	2,246	senior vice president
Dec 29, 2023	talor eyal	acquired	2,399	2.72	882	chief scientific officer
Dec 29, 2023	kersten geert r	acquired	4,947	2.72	1,819	chief executive officer
Dec 29, 2023	prichep patricia b	acquired	4,289	2.72	1,577	senior vice president
Sep 29, 2023	talor eyal	acquired	2,400	1.25	1,920	chief scientific officer
Sep 29, 2023	kersten geert r	acquired	4,950	1.25	3,960	chief executive officer
Sep 29, 2023	prichep patricia b	acquired	4,290	1.25	3,432	senior vice president
Jun 30, 2023	prichep patricia b	acquired	4,289	2.41	1,780	senior vice president

Which funds bought or sold CVM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Latitude Advisors, LLC	sold off	-100	-43,982	-	-%
Apr 25, 2024	Allworth Financial LP	unchanged	-	-98.00	232	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	added	10.08	-18,000	59,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-73,157	-	-%
Apr 24, 2024	Costello Asset Management, INC	unchanged	-	-2,511	5,921	-%
Apr 23, 2024	NATIONS FINANCIAL GROUP INC, /IA/ /ADV	unchanged	-	-12,150	28,650	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	unchanged	-	-15,291	36,057	-%
Apr 11, 2024	Hyperion Partners, LLC	unchanged	-	-11,421	26,931	0.02%
Apr 11, 2024	City State Bank	unchanged	-	-1,000	4,000	-%
Apr 05, 2024	NBC SECURITIES, INC.	new	-	1,000	1,000	-%

Are Funds Buying or Selling CVM?

Are funds buying CVM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CVM

No. of Funds

Unveiling CEL-SCI Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 08, 2023	state street corp	0.5%	218,207	SC 13G/A
Jul 08, 2022	blackrock inc.	2.7%	1,153,102	SC 13G
Apr 11, 2022	state street corp	2.27%	980,339	SC 13G/A
Feb 11, 2022	state street corp	7.79%	3,368,998	SC 13G/A
Feb 01, 2022	blackrock inc.	6.8%	2,942,209	SC 13G/A
Oct 12, 2021	state street corp	10.64%	4,576,724	SC 13G/A
Jan 29, 2021	blackrock inc.	6.2%	2,472,437	SC 13G/A
Feb 07, 2020	blackrock inc.	5.6%	1,996,547	SC 13G

Recent SEC filings of CEL-SCI Corp

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	3	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	8-K	Current Report
Apr 19, 2024	8-K	Current Report
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading

Peers (Alternatives to CEL-SCI Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

CEL-SCI Corp News

Latest updates

CEL-SCI Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2017Q2	2017Q1	2016Q3	2016Q2	2016Q1	2015Q3	2015Q2	2015Q1	2014Q4	2014Q3	2014Q2	2014Q1	2013Q4	2013Q3	2013Q2	2013Q1
Revenue	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	7.5%	6.00	5.00	4.00	5.00	4.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	-1.0%	2.00	2.00	2.00	2.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	14.3%	3.00	3.00	3.00	3.00	3.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-0.7%	-0.45	-0.44	-0.46	-0.45	5.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-Infinity%	-4.85	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	59.9%	-4.85	-12.08	-6.45	1.00	-14.93	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-6.0%	29.00	31.00	32.00	38.00	45.00	51.00	57.00	64.00	70.00	76.00	80.00	48.00	50.00	41.00	44.00	37.00	31.00	28.00	28.00	25.00	26.00
Current Assets	-11.0%	6.00	7.00	8.00	13.00	20.00	25.00	31.00	37.00	42.00	45.00	50.00	20.00	24.00	18.00	23.00	16.00	11.00	10.00	11.00	7.00	8.00
Cash Equivalents	-21.8%	3.00	4.00	5.00	10.00	18.00	23.00	28.00	34.00	37.00	36.00	36.00	6.00	22.00	16.00	20.00	14.00	9.00	8.00	9.00	6.00	7.00
Inventory	4.4%	2.00	2.00	-	-	-	2.00	-	-	-	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Net PPE	-5.3%	10.00	10.00	11.00	11.00	12.00	12.00	12.00	13.00	13.00	14.00	14.00	13.00	9.00	6.00	4.00	3.00	3.00	16.00	16.00	16.00	16.00
Liabilities	-7.2%	16.00	17.00	18.00	18.00	18.00	18.00	18.00	19.00	18.00	19.00	20.00	19.00	21.00	21.00	23.00	23.00	23.00	22.00	27.00	24.00	23.00
Current Liabilities	-12.9%	5.00	6.00	5.00	5.00	5.00	5.00	4.00	4.00	3.00	4.00	5.00	6.00	7.00	4.00	5.00	5.00	5.00	3.00	4.00	5.00	6.00
Shareholder's Equity	-4.3%	13.00	13.00	15.00	20.00	27.00	32.00	39.00	45.00	51.00	57.00	60.00	29.00	29.00	20.00	21.00	14.00	9.00	5.00	1.00	1.00	3.00
Retained Earnings	-1.4%	-493	-487	-479	-471	-462	-454	-446	-436	-426	-418	-409	-401	-389	-381	-376	-366	-357	-353	-348	-336	-330
Additional Paid-In Capital	1.2%	506	500	494	491	489	487	485	481	478	474	469	430	418	401	397	380	366	359	350	337	333
Shares Outstanding	5.5%	50.00	47.00	45.00	44.00	44.00	43.00	43.00	43.00	43.00	43.00	41.00	40.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	-	98.00	-	-	-	596	-	-	-	412	-	-	-	100	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	3.1%	-4,887	-5,044	-5,665	-7,471	-4,666	-4,913	-5,789	-2,731	-4,805	-4,802	-5,200	-4,956	-3,827	-3,586	-3,699	-3,888	-4,101	-3,887	-4,643	-3,632	-4,157
Share Based Compensation	5.7%	1,384	1,310	1,540	1,743	1,693	2,287	2,448	3,393	3,262	3,595	3,511	3,283	3,296	3,423	3,109	1,781	1,800	1,802	1,522	531	574
Cashflow From Investing	-525.5%	-64.86	-10.37	-196	-111	-53.58	-16.07	-70.96	-533	6,112	4,590	-1,999	-14,624	-3,149	-1,124	-803	-657	-109	-49.04	-58.22	-156	-72.26
Cashflow From Financing	-0.4%	4,048	4,066	952	-388	65.00	-471	-348	438	-256	315	36,726	4,152	13,329	83.00	10,310	9,492	5,150	2,895	8,673	2,621	602

CVM Income Statement

2023-12-31

CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 4,352,509	$ 5,392,546
General and administrative	2,133,378	2,258,003
Total operating expenses	6,485,887	7,650,549
Operating loss	(6,485,887)	(7,650,549)
Interest expense, net	(197,696)	(152,789)
Other expense	(25,941)	(50,171)
Net loss	(6,709,524)	(7,853,509)
Modification of warrants	0	(171,552)
Net loss available to common shareholders	$ (6,709,524)	$ (8,025,061)
Net loss per common share - basic and diluted	$ (0.14)	$ (0.18)
Weighted average common shares outstanding - basic and diluted	48,470,600	43,440,387

CVM Balance Sheet

2023-12-31

CONDENSED BALANCE SHEETS - USD ($)	Dec. 31, 2023	Sep. 30, 2023
Current assets:
Cash and cash equivalents	$ 3,241,440	$ 4,145,735
Prepaid expenses	549,835	520,368
Supplies used for R&D and manufacturing	2,347,049	2,248,072
Deposits	16,129	4,245
Total current assets	6,154,453	6,918,420
Finance lease right of use assets	8,680,732	9,131,987
Operating lease right of use assets	1,649,020	1,698,243
Property and equipment, net	9,644,158	10,188,126
Patent costs, net	188,294	197,704
Deposits	2,319,101	2,319,101
Supplies used for R&D and manufacturing	74,457	74,669
Total assets	28,710,215	30,528,250
Current liabilities:
Accounts payable	1,144,425	2,009,786
Accrued expenses	985,657	1,049,581
Due to employees	705,698	557,244
Finance lease obligation, current portion	1,827,363	1,771,804
Operating lease obligation, current portion	204,167	197,431
Total current liabilities	4,867,310	5,585,846
Finance lease obligations, net of current portion	9,468,149	9,949,565
Operating lease obligations, net of current portion	1,599,496	1,652,949
Other liabilities	125,000	125,000
Total liabilities	16,059,955	17,313,360
STOCKHOLDERS' EQUITY
Preferred stock, $.01 par value; 200,000 shares authorized; 0 shares issued and outstanding	0	0
Common stock, $.01 par value; 600,000,000 shares authorized; 50,018,601 and 47,422,304 shares issued and outstanding at December 31, 2023 and September 30, 2023, respectively	500,186	474,223
Additional paid-in capital	505,950,994	499,832,063
Accumulated deficit	(493,800,920)	(487,091,396)
Total stockholders' equity	12,650,260	13,214,890
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 28,710,215	$ 30,528,250

About CEL-SCI Corp

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

WEBSITE	https://cel-sci.com
INDUSTRY	Biotechnology

CEL-SCI Corp Frequently Asked Questions

What is the ticker symbol for CEL-SCI Corp? What does CVM stand for in stocks?

CVM is the stock ticker symbol of CEL-SCI Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CEL-SCI Corp (CVM)?

As of Fri Apr 26 2024, market cap of CEL-SCI Corp is 71.15 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CVM stock?

You can check CVM's fair value in chart for subscribers.

What is the fair value of CVM stock?

You can check CVM's fair value in chart for subscribers. The fair value of CEL-SCI Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of CEL-SCI Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CVM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is CEL-SCI Corp a good stock to buy?

The fair value guage provides a quick view whether CVM is over valued or under valued. Whether CEL-SCI Corp is cheap or expensive depends on the assumptions which impact CEL-SCI Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CVM.

What is CEL-SCI Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, CVM's PE ratio (Price to Earnings) is -2.29 and Price to Sales (PS) ratio is 253.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CVM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on CEL-SCI Corp's stock?

In the past 10 years, CEL-SCI Corp has provided -0.261 (multiply by 100 for percentage) rate of return.